Moxifloxacin Orion

Moxifloxacin, the active ingredient in Moxifloxacin Orion, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including pneumonia, sinusitis, and intra‑abdominal infections.

GNH USA supplies Moxifloxacin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin Orion is a fluoroquinolone antibiotic used to manage bacterial infections affecting various organ systems.

Community‑acquired bacterial pneumonia: achieves rapid bacterial eradication and improves respiratory function. Acute bacterial sinusitis: reduces sinus inflammation by eliminating pathogenic bacteria. Skin and soft‑tissue infections: clears infection and promotes wound healing. Complicated intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms. Acute bacterial exacerbation of chronic bronchitis: diminishes bacterial load to alleviate bronchial symptoms.

Moxifloxacin Orion may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Transient dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur during or after therapy. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe allergic reaction: anaphylaxis, angioedema, or bronchospasm. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Hepatotoxicity: rare cases of liver injury.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications. - Renal impairment: adjust therapy based on renal function. - Hepatic disease: use with caution in patients with liver dysfunction. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Concomitant corticosteroids: monitor for increased tendon injury risk. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin Orion can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increased arrhythmia risk. - Antacids or supplements containing aluminum, magnesium, calcium, or iron: reduce absorption. - Warfarin: may enhance anticoagulant effect and bleeding. - Theophylline: increased plasma concentrations.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened risk of tendon rupture. - NSAIDs: potential for central nervous system stimulation. - Oral hypoglycemics: may cause hypoglycemia. - Cyclosporine: possible increase in serum levels. - Digoxin: monitor for altered cardiac effects.